Ozempic Results After 1 Year: Realistic Weight Loss Expectations

Introduction

A year on Ozempic® is the point where the question shifts from “is this working” to “what does the rest of my life with this medication look like.” By month 12 you have lived through the easy losses, the first real plateau, and probably a dose decision or two. The scale and the clothes have settled into a new baseline.

The realistic 12 month figure on Ozempic is 12 to 15 percent of starting body weight, with patients on 2 mg tracking near the top of that range. That is roughly 25 to 35 pounds for someone who started at 220 pounds. Trial data from SUSTAIN and STEP, plus real-world clinic numbers, all cluster in that window.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Much Weight Do People Lose in 1 Year on Ozempic?

The mean 1 year weight loss on Ozempic is 12 to 15 percent of starting body weight for adherent patients on 1 mg or 2 mg dosing. That works out to 24 to 33 pounds for a 220 pound starting weight or 30 to 40 pounds at 270 pounds.

Quick Answer: Typical 1 year loss on Ozempic is 12 to 15 percent of starting body weight

STEP 1 (Wilding et al. 2021 NEJM) is the best public dataset for semaglutide at this time horizon, using 2.4 mg in 1,961 adults with obesity. Mean weight loss was 14.9 percent at week 68, which translates to about 13.5 percent at week 52.

Ozempic at 2 mg, which is the highest approved dose, typically tracks 1 to 2 percentage points below STEP 1 because the dose is lower. SUSTAIN-FORTE (Frias 2021 Lancet Diabetes Endocrinol) showed Ozempic 2 mg delivers extra benefit over 1 mg but not equivalent to Wegovy® 2.4 mg.

Real-world adherence is the wildcard. Gasoyan and colleagues’ 2024 follow-up in JAMA Network Open reported only 41 percent of patients prescribed semaglutide for obesity were still on therapy at 12 months. Those who stayed lost 7.4 percent on average, those who stopped early lost 3.6 percent.

What Does the Year 1 Plateau Look Like?

The 1 year plateau usually starts between week 40 and 60 and represents the point where adaptive thermogenesis matches the GLP-1 appetite effect. The scale stops moving in either direction for weeks at a time, with body composition still slowly improving.

STEP 1 weight loss curves show the steepest slope in weeks 0 to 20, a gentler slope from week 20 to 50, and a near-flat segment from week 50 to 68. The plateau is biological, not behavioral, and trying to push through it with aggressive deficits usually backfires.

A 2014 Obesity journal paper by Sumithran and Proietto reviewed appetite hormone changes after weight loss and found ghrelin, leptin, peptide YY, and other markers stay shifted toward weight regain for at least 12 months after a major loss. GLP-1 medications blunt this defense but do not eliminate it.

Patients who keep losing past month 12 usually share two traits: consistent resistance training and high protein intake. Without those, the plateau is permanent and slight regain creeps in by month 14 or 15.

How Do Year 1 Metabolic Results Compare to Year 1 Weight Results?

Metabolic improvements at year 1 are often more clinically meaningful than the weight loss itself. A1c reductions of 1.5 to 2.0 percentage points, systolic blood pressure drops of 5 to 8 mmHg, and significant lipid panel shifts are common.

SUSTAIN-6 (Marso et al. 2016 NEJM) tracked 3,297 high-risk type 2 diabetes patients for 2 years and reported 26 percent fewer major adverse cardiovascular events on semaglutide. Most of the surrogate benefit, A1c, blood pressure, microalbuminuria, was visible by month 12.

SELECT (Lincoff et al. 2023 NEJM), the cardiovascular outcomes trial in 17,604 non-diabetic adults with obesity and CVD, showed 20 percent MACE reduction on 2.4 mg semaglutide over a mean 39 months. The early metabolic curves overlap with Ozempic at full dose.

FLOW (Perkovic et al. 2024 NEJM), which enrolled 3,533 patients with type 2 diabetes and chronic kidney disease, showed 24 percent reduction in kidney failure and CV death over 3.4 years on 1 mg semaglutide. Kidney function stabilization was apparent in the first year.

What Happens If You Stop Ozempic at 1 Year?

Stopping Ozempic at 1 year typically leads to regaining about two-thirds of the lost weight within 12 months. This is the central finding from the STEP 4 extension (Rubino et al. 2021 JAMA), which randomized patients off semaglutide after a lead-in and tracked regain.

The STEP 4 design ran a 20 week lead-in on 2.4 mg semaglutide, then randomized 803 responders to continue or switch to placebo for another 48 weeks. The placebo group regained 6.9 percent of body weight while the continuation group lost another 7.9 percent.

The biological reason is the appetite hormone shift Sumithran documented. When semaglutide leaves the system, ghrelin rebounds, satiety signaling drops, and gastric emptying accelerates. Patients describe a sharp return of food noise within 2 to 3 weeks.

The practical implication is that Ozempic at 1 year should be viewed like a blood pressure medication, ongoing rather than time-limited. Many providers do try lower maintenance doses, 0.5 mg or 1 mg, after the loss phase to preserve results at lower cost and side effect burden.

Are 2 Mg Results Meaningfully Better at 1 Year?

Ozempic 2 mg outperforms 1 mg modestly at 1 year, adding about 1 to 2 percentage points of body weight loss and 0.2 to 0.3 points of A1c reduction. The gain is real but smaller than many patients expect.

SUSTAIN-FORTE (Frias et al. 2021 Lancet Diabetes Endocrinol) randomized 961 patients to 1 mg or 2 mg for 40 weeks. The 2 mg group lost 6.9 kg versus 6.0 kg on 1 mg, an extra 0.77 kg, and saw an additional 0.23 percent A1c drop.

Patients who want significantly more loss usually switch to tirzepatide rather than max out Ozempic. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9 percent loss at 72 weeks on tirzepatide 15 mg, well above the 14.9 percent STEP 1 ceiling for semaglutide.

The clinical question at 1 year is whether 2 mg is worth the dose increase given the modest extra effect. For patients with persistent A1c elevation it usually is. For weight-only goals, switching agents is often the better move.

Key Takeaway: Most patients hit a stable plateau between months 9 and 14

How Do Real-world 1 Year Results Compare to Trial Data?

Real-world 1 year results are notably lower than trial averages, mostly because adherence drops sharply over the year. Trial settings provide free medication, monitoring, and structured support that translate to better outcomes.

The Cleveland Clinic retrospective (Gasoyan et al. 2024 JAMA Network Open) on 7,881 adults with obesity on semaglutide showed 30 percent discontinued by 3 months and 59 percent by 12 months. Adherent patients lost 7.4 percent at 12 months; the overall cohort lost just 3.6 percent.

Cost and supply issues drive most discontinuations. Ozempic shortages in 2022 and 2023 forced switches and gaps that interrupted progress for many. Insurance coverage for non-diabetic use remains uneven.

Telehealth platforms like TrimRx that handle compounded semaglutide can sidestep some of these issues by avoiding insurance and shortage cycles, though brand-name access has improved in 2025 and 2026. The free assessment quiz is where new patients usually start.

What Does the Year 1 Protocol Look Like for the Next Year?

The standard protocol after a successful 1 year on Ozempic is continued therapy at the maintenance dose, with optional dose reduction if weight is stable and side effects are bothersome. The SELECT trial extension data supports continued dosing for cardiovascular benefit.

A common protocol shift at month 12 is dropping from 2 mg to 1 mg or from 1 mg to 0.5 mg, then watching for 3 months. If weight stays flat at the lower dose, that becomes the long-term maintenance dose. If regain starts within 8 to 12 weeks, the prior dose is reinstated.

Lifestyle work matters more in year 2 than in year 1. The weight is off, the GLP-1 dose is doing less of the heavy lifting, and habits become the primary driver. Resistance training, sleep, protein, and consistent step count are the levers that hold the result.

Lab monitoring at month 12 typically includes A1c, lipid panel, kidney function, liver enzymes, and sometimes vitamin B12 because semaglutide can blunt B12 absorption over time. TrimRx’s personalized treatment plan covers annual labs and maintenance dose adjustments.

Is There a Point at Which Ozempic Stops Working?

Ozempic does not stop working in a true pharmacological sense, but the weight loss curve flattens permanently between months 14 and 18 for most patients. Continued therapy maintains the loss; it does not keep extending it.

The STEP 1 extension data and SUSTAIN long-term cohorts both show weight stabilizing rather than continuing to drop after month 18. The appetite suppression remains effective, so regain doesn’t happen on therapy, but new loss is rare without significant behavior change.

Patients who want additional loss after this point usually combine Ozempic with structured calorie awareness, switch to tirzepatide, or add bariatric surgery in extreme cases. Adding a stimulant-type appetite suppressant on top of GLP-1 is generally not done outside clinical trials.

A1c and other metabolic markers continue improving past month 18 as long as therapy continues. The cardiovascular and kidney protection visible in SELECT and FLOW grows over multiple years, not just year 1.

Bottom line: Long-term cardiovascular and metabolic benefits compound through year 1 and beyond

FAQ

Can You Lose 50 Pounds in 1 Year on Ozempic?

Fifty pounds in 1 year is possible for patients starting above 280 pounds, where 50 pounds represents about 18 percent body weight loss. For lighter starting weights it is uncommon. Switching to tirzepatide opens up a higher loss ceiling.

How Much Weight Do You Regain After Stopping Ozempic?

STEP 4 (Rubino 2021 JAMA) showed about two-thirds regain within 12 months of stopping. That means a patient who lost 30 pounds typically regains 20 pounds in the year after stopping.

Is Ozempic Safe to Take for Years?

Long-term safety data through 2 to 3 years from SUSTAIN-6, SELECT, and FLOW shows a strong safety profile, with thyroid C-cell tumors, pancreatitis, and gallbladder disease as the main flagged risks. Annual monitoring is the standard practice.

Does Ozempic Stop Working After a Year?

No, but weight loss usually plateaus between months 14 and 18. Therapy continues to maintain the lost weight and deliver cardiovascular and metabolic protection. New loss after the plateau is uncommon without dose escalation or agent switching.

What’s the Best Dose for Long-term Ozempic Maintenance?

Many providers move from 1 mg or 2 mg down to 0.5 mg or 1 mg after the initial loss phase for long-term maintenance. The lower dose preserves most of the weight loss while reducing side effects and cost.

Do You Need to Be on Ozempic Forever?

Most patients who want to keep the weight off stay on some GLP-1 long-term. Obesity is increasingly framed as a chronic condition by ADA, Endocrine Society, and AACE guidelines, with GLP-1 therapy as ongoing rather than time-limited.

Will My Labs Really Improve by 1 Year on Ozempic?

For most patients, yes. A1c typically drops 1.5 to 2.0 percentage points, blood pressure falls 5 to 8 mmHg, triglycerides drop 20 to 30 percent, and inflammatory markers like hs-CRP often improve. These changes match what SUSTAIN-6 and SELECT documented.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.